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Hepatitis B Virus core (HBc) particles have been studied for their potential as drug delivery vehicles for
cancer therapy. HBc particles are hollow nano-particles of 30e34 nm diameter and 7 nm thick envelopes,
consisting of 180e240 units of 21 kDa core monomers. They have the capacity to assemble/dis-assemble
in a controlled manner allowing encapsulation of various drugs and other biomolecules. Moreover, other
functional motifs, i.e. receptors, receptor binding sequences, peptides and proteins can be expressed. This
study focuses on the development of genetically modified HBc particles to specifically recognise and
target human epidermal growth factor receptor-2 (HER2)-expressing cancer cells, in vitro and in vivo, for
future cancer therapy. The non-specific binding capacity of wild type HBc particles was reduced by
genetic deletion of the sequence encoding arginine-rich domains. A specific HER2-targeting was ach-
ieved by expressing the ZHER2 affibodies on the HBc particles surface. In vitro studies showed specific
uptake of ZHER2-DHBc particles in HER2 expressing cancer cells. In vivo studies confirmed positive uptake
of ZHER2-DHBc particles in HER2-expressing tumours, compared to non-targeted DHBc particles in
intraperitoneal tumour-bearing mice models. The present results highlight the potential of these
nanocarriers in targeting HER2-positive metastatic abdominal cancer following intra-peritoneal
administration.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The effectiveness of detecting and treating cancer has remained
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r Ltd. This is an open access articletumour drugs to achieve a therapeutic effect without causing se-
vere systemic side effects has proven to be challenging [2]. To
address these issues, many efforts have been put into developing
specific targeted carriers that can deliver the desired cargo selec-
tively to tumour sites.
Virus-like particles (VLPs) provide an alternative platform for
cell-targeted therapeutic delivery. VLPs are attractive as they are
self-assembled, uniform, have well-defined geometry and are able
to be tailored at an amino acid level by genetic modification [3].
Moreover, they form a closed structure that defines an interior
environment capable of housing therapeutic or imaging agents and
an exterior surface capable of multivalent presentation of targeting
moieties [4,5]. Hepatitis B Virus core (HBc) particles, examples of
VLPs, have attracted many researchers as promising nanocarriersunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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HBc particles are hollow nanoparticles, 30e34 nm in diameter
with 7 nm thickness envelopes, consisting of 180e240 units of
21 kDa core monomers [7,8]. They are capable of non-specific
binding to various cell types via the action of positively-charged
arginine-rich domain. However, the arginine-rich domain of the
core protein is not critical for the particle assembly [7,9,10]. The
major immunodominant region (MIR) of HBc particles, located at
the 78e83 amino acids (aa), is able to express immunological
epitopes [11]. It has been shown that other functional motifs i.e.,
receptors [12], proteins [13] and element recognising low molec-
ular mass substrates [14], can be expressed by genetic modification
to this region.
Recently, affibody molecules, a new class of affinity ligands
derived from the Z-domain in the binding region of Staphylococcus
aureus protein A [15], have been the focus of researchers as a viable
alternative to antibodies. Among the types of affibodies, mono-
meric ZHER2:342 (hereafter ZHER2) can specifically bind the HER2
over-expressed on the cell membrane surface of breast cancer and
ovarian cancer cells [16]. Due to this attractive property, ZHER2
affibody makes a suitable targeting moiety to facilitate HER2 tar-
geting by the nanocarriers.
In this study, we focused on the development of genetically
modified HBc particles to specifically recognise and target HER2-
expressing cancer cells in vitro and in vivo, qualitatively and
quantitatively, for nucleic acid delivery applications. HER2 target-
ing was achieved by expression of ZHER2 affibodies in the HBc
monomer. HBc particles were prepared using the E. coli expression
system. HBc particles morphology was confirmed by atomic force
microscopy (AFM) and cryo transmission electron microscopy
(Cryo-TEM). Protein specificity was confirmed by Western blotting.
A range of cells expressing different levels of HER2 were treated
with fluorescently labelled HBc particles and the cell uptake was
assessed using flow cytometry. HBc particles were then radio-
labelled with technetium-99m (99mTc), using the previously re-
ported hexahistidine sequence (His-tag) labelling protocol [17].
Single-photon emission computed tomography/computerised to-
mography (SPECT/CT) imaging and quantitative gamma counting
were performed to characterise the organ biodistribution profile of
the HER2 specific-targeting HBc particles in tumour-bearing mice.
2. Materials and methods
2.1. Materials
Please refer to Supporting information for the list of materials
used.
2.2. Methods
2.2.1. Expression, purification and assembly of HBc particles
E. coli BL21 (DE3) was transformed with plasmids for expression
of wild type HBc, DHBc or ZHER2-DHBc cultured in 10 mL of Auto-
Induction Media Terrific broth (AIM-TB) media in the presence of
100 mg/mL ampicillin and grown at 37 C for 16 h using an incubator
shaker. The culture was then diluted with 500 mL of fresh AIM-TB
media in the presence of 100 mg/mL ampicillin and grown at 25 C
for 72 h. Cells were harvested at 5000 rpm, 4 C for 15 min. Pelleted
cells were re-suspended in the 30 ml of lysis buffer (50 mM Tris,
100 mM NaCl, 5 mM EDTA, 0.2% Triton X-100, 1x cOmplete™ pro-
tease inhibitor pH 8.0). The cells were treated with RNase A at final
concentration 5 mg/mL at 4 C for overnight. The lysate was soni-
cated using a probe sonicator on ice by three cycles for 1 min each
with 1 min intervals to avoid heating the material. The supernatant
was removed by centrifugation at 12,000 rpm, 4 C for 30 min. Thecore particles in the cell pellet were washed in 30 ml of lysis buffer
and collected by centrifugation at 12,000 rpm, 4 C for 30 min. The
cell pellet containing HBc, DHBc or ZHER2-DHBc particles was de-
natured in 40 ml of dissociation buffer (8 M urea, 200 mM NaCl,
50 mM sodium carbonate, 10 mM 2-mercaptoethanol, pH 9.5) by
overnight incubation at 4 C. Then, the pellet was discarded by
centrifugation at 12,000 rpm, 4 C for 30 min.
Soluble fraction containing-contaminating proteins were sepa-
rated from HBc particle proteins using Ni2þ-chelate affinity chro-
matography. A column with 6 mL of cOmplete™ His-Tag
Purification Resin (Roche, Germany) was equilibrated with 3-
times bed-volume (18 mL) of dissociation buffer. The column was
loaded with the protein probe and washed with 18 mL of dissoci-
ation buffer. Bound HBc particle proteins were eluted with 14 mL of
elution buffer (2 M urea, 200 mM NaCl, 50 mM sodium carbonate,
10 mM 2-mercaptoethanol, 1 M imidazole, pH 9.5). The eluted
material was collected in 1 mL fractions. The aliquots of each
fraction were subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and stained with
Coomassie Brilliant Blue (CBB) to analyse their purity.
Fractions containing the HBc protein were re-assembled to
particles by the removal of the urea. Specifically, protein fractions
were dialysed against 2 L of dialysis buffer 1 (0.5 M urea, 100 mM
Tris, 150 mM NaCl, 2 mM DTT, 1 mM EDTA, 10 mM CaCl2, pH 8.0)
using SnakeSkin™ Dialysis Tubing, 10K MWCO (Thermo Scientific,
USA) at 4 C for 4 h, allowing HBc protein to start assembling. Then,
the solution was dialysed against dialysis buffer 2 (100 mM Tris,
150 mM NaCl, 1 mM EDTA, 10 mM CaCl2, pH 8.0) to completely
removed urea and DTT, to fully assemble the HBc particles. HBc
particles were filtered using 0.44 mm filter to remove any aggre-
gates. All protein concentrations were measured using NanoDrop™
ND-1000 UVeVis Spectrophotometer (Thermo Fisher Scientific,
USA).
2.2.2. Atomic force microscopy (AFM) analysis of purified HBc
particles
One hundred microliter of 10 mg/mL of purified wild type HBc,
DHBc or ZHER2-DHBc particles was deposited on mica surfaces for
5 min and then flushed with air. Tapping mode AFM analysis (TM-
AFM) on the mica substrates were carried out in air at 25 C using a
Bruker Dimension ICONwith Scan Assist. The surfaces were imaged
with a general purpose-tapping tip made byMikroMasch in Estonia
(NSC15/no Al, tip radius < 10 nm; tip height ¼ 20e25 mm; cone
angle < 40; cantilever thickness ¼ 3.5e4.5 mm; cantilever
width ¼ 32 -28 mm; cantilever length ¼ 120e130 mm; frequency
f0 ¼ 265e400 kHz; force constant k ¼ 20e75 N m1, VEECO, USA).
The statistical analysis of the AFM images was carried out using
WSxM v5.0 Developed 6.2 software (Spain).
2.2.3. Cryo-transmission electron microscopy (Cryo-TEM) of HBc
particles
The shape, morphology and size distribution of HBc particles
was evaluated using low electron dose cryo-transmission electron
microscopy (cryo-TEM). Cryo-TEM enables the investigation of
colloidal dispersion [18] and biological origin samples like viruses
[19] and proteins [20], close to their native state. A drop of solution
(3 ml) was applied on hydrophilic TEM Quantifoil grids. The grids
were then blotted for 2 s and plunged into the liquid ethane pool
using a FEI Vitrobot mark IV, in order to produce a thin vitreous ice
layer with embedded assemblies in the holes of the grid. Digital
cryo-TEM images were acquired using a FEI Tecnai Spirit operated
at 120 kV using a Gatan 626 cryo-transfer tomography holder.
2.2.4. SDS-PAGE and western blot analysis of WT-HBc particles
The expression of each WT-HBc, DHBc or ZHER2-DHBc monomer
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and ZHER2-DHBc particles were analysed by SDS-PAGE and electro-
transferred onto a nitrocellulose membrane. For the detection of
the His6-tag, rabbit anti-6-His antibody (Bethyl Laboratories, USA)
was used as a primary antibody at 1:1000 dilution for immuno-
blotting, followed by HRP-linked anti-rabbit (Cell Signalling Tech-
nology, USA) at 1:1000 dilution and Precision Protein StrepTactin-
HRP Conjugate (Bio-Rad Laboratories, USA) at 1:10,000 dilution
for secondary antibody. For the detection of the His6-tag, mouse
anti-HBc antibody (Merck Millipore, USA) was used as a primary
antibody at 1:1000 dilution for immunoblotting, followed by HRP-
linked anti-mouse (Cell Signalling Technology, USA) at 1:1000
dilution and Precision Protein StrepTactin-HRP Conjugate (Bio-Rad
Laboratories, USA) at 1:10,000 dilution for secondary antibody. The
specific bands were detected with enhanced chemiluminescence
(ECL) detection system. The membrane was imaged using the
ChemiDoc™MP (Bio-Rad Laboratories, USA) and analysed with
Image Lab (Bio-Rad Laboratories, USA) software.
2.2.5. Fluorescence labelling of HBc particles
Purified HBc particles were reacted with Alexa Fluor™ 488
Succinimidyl Esters (Invitrogen Life Technologies, USA) at 40:1
HBc:dye mass ratio in phosphate-buffered saline (PBS) buffer for
1 h at room temperature with stirring. The mixture was then dia-
lysed using SnakeSkin™ Dialysis Tubing, 10K MWCO (Thermo Sci-
entific, USA) against PBS buffer at 4 C for overnight to remove free
Alexa Fluor™ 488. To evaluate the fluorescence labelling efficiency,
a standard curve of Alexa Fluor™ 488-labelled WT-HBc, DHBc or
ZHER2- DHBc was prepared. Fluorescence intensity was measured at
485 nm and 520 nm excitation and emission wavelengths,
respectively, at 25 C using a BMG FLUOstar Omega fluorometer.
2.2.6. Cell culture
A panel of cell lines, of varied degree of HER2 expression, was
used in this study. The MDA-MB-435-MLE human melanoma
(parent cell line: MDA-MB-435; ATCC, HTB-129) were cultured in
DMEM media supplemented with 10% FBS, 50 U/mL penicillin,
50 mg/mL streptomycin, 1% L-glutamine, at 37 C in 5% CO2. MDA-
MB-435-MLE cells were obtained by transfecting the parent cell
line MDA-MB-435 with MUC1, luciferase and ErbB2 genes as pre-
viously reported [21]. MDA-MB-435-MLE was a kind gift from Dr
John Maher (Research Oncology Group, King's College London, UK).
The MDA-MB-468 human breast adenocarcinoma (MDA-MB-468;
ATCC, HTB-132), MDA-MB-231 human breast carcinoma (MDA-MB-
231; ATCC, HTB-26), SKBR-3 human breast carcinoma (SKBR3;
ATCC, HTB-30) and BT-474 human breast ductal carcinoma (BT-474;
ATCC, HTB-20) were cultured in DMEM media supplemented with
10% FBS, 50 U/mL penicillin, 50 mg/mL streptomycin, 1% L-gluta-
mine, at 37 C in 5% CO2. All cells were routinely grown in 75 cm2
canted-neck tissue culture flasks and passaged twice a week using
Trypsin/EDTA at 80% confluency.
2.2.7. Uptake studies in vitro by flow cytometry
MDA-MB-468, MDA-MB-231, SKBR-3 and BT-474 cells were
seeded at a density of 1  105 cells/mL in 24-well plates and
allowed to attach overnight. After washing with PBS buffer, cells
were then treated with fluorescent Alexa Fluor™ 488-labelled HBc,
DHBc or ZHER2-DHBc particles at increasing concentrations of 10, 20
or 40 mg/mL in serum-free media for 1, 4 or 24 h. For the 24 h
treatment, after 4 h incubation, FBS was added to eachwell to reach
10% v/v final FBS concentration. Cells were re-incubated for another
20 h. After treatment, cells were washed twice with PBS buffer,
trypsinised and centrifuged at 1500 rpm for 5 min and the cell
pellet was re-suspended in 250 ml of PBS buffer. The internalisation
of HBc particles was studied on 10,000 gated cells by detectingAlexa Fluor™ 488 fluorescence using FL-1 channel detector and BD
FACS Calibur flow cytometer (BD Biosciences, USA). The measure-
ments were done in triplicate and the data were analysed using BD
CellQuest software (BD Biosciences, USA).
2.2.8. Preparation of [99mTc(CO3)]
þ
IsoLink kits (Mallinckrodt Medical BV, Petten, Netherlands)
were reconstituted in 1 mL deionised water and subdivided into
aliquots of 260 mL in microcentrifuge tubes. Aliquots were stored
at 80 C. Upon use, an aliquot of the reconstituted kits were
allowed to thaw at room temperature, andwere added to 1.5 GBq of
500 mL [99mTcCO4]- (St. Bartholomew's Hospital Radiopharmacy,
London, UK) in glass vial and incubated for 30 min at 100 C. The
glass vial was then allowed to cool on ice and shortly centrifuged at
room temperature to accumulate any condensed solution. The so-
lution was then neutralised with 40 mL of 1 M HCl to pH approxi-
mately 7.0, giving a total of volume of 800 ml of [99mTc(CO3)]þ. A
needle was inserted to vent the gas generated from the reaction.
2.2.9. [99mTc(CO3)]þ radiolabelling of HBc particles and serum
stability
NaCl, at 5.5 M, was added to [99mTc(CO3)]þ at a 1:1 vol ratio in a
microcentrifuge tube to achieve a final [Na]þ salt concentration of
0.63 M at the end of the labelling reaction. For gamma counting
studies, DHBc (1 mg/mL) or ZHER2-DHBc (1 mg/mL) particles in PBS
buffer were radiolabelled by incubating 100 ml of each protein so-
lution with up to 20 MBq in 20 ml of Naþ-[99mTc(CO3)]þ. For SPECT/
CT imaging, both HBc particles (2 mg/mL) were also radiolabelled
with up to 75 MBq in 80 ml of Naþ-[99mTc(CO3)]þ. The labelling
reaction was carried out at 37C and monitored for 2 h with
labelling efficiency determined at 60 and 120min using instant thin
layer chromatography (iTLC) using citrate buffer as the mobile
phase. This system provided a good separation between the
[99mTc(CO3)]þ-labelled HBc particles and unbound [99mTc(CO3)]þ.
Strips were allowed to dry before being developed and counted
quantitatively using a cyclone phosphor detector (Packard Bio-
sciences, UK). The 99mTc-DHBc and 99mTc-ZHER2-DHBc particles
were buffer exchanged to PBS buffer using Vivaspin MWCO 10 kDa
before being injected into animals. This also ensured that no un-
bound [99mTc(CO3)]þ was present prior to injection. Solutions of
purified 99mTc-DHBc and 99mTc-ZHER2-DHBc particles (~200 ml per
injection dose, 50 mg of protein) were collected and examined again
by iTLC.
The stability of radiolabelled 99mTc-DHBc and 99mTc-ZHER2-DHBc
particles was determined by incubating 5 mL of each sample with
serum (5 mL) or PBS (5 mL) at 37 C. After 24 h, 5 mL of the incubated
samples were spotted to the iTLC paper strips, which were devel-
oped and quantified as described above. Unbound [99mTc(CO3)]þ
was detected at the solvent front while [99mTc(CO3)]þ-labelled HBc
particles was retained at the solvent front.
2.2.10. Animal studies and tumour inoculation
All animal experiments were performed in compliance with the
UK Home Office (1989) Code of Practice for the housing and care of
Animals used in Scientific Procedures.
For intraperitoneal model, the harvested MDA-MB-435-MLE
cells were suspended in PBS buffer (pH 7.4) and injected intraper-
itoneally in the male NSG mice aged 4e6 weeks (Charles River, UK)
at a concentration of 5.0  106 cells in 100 mL. For the mammary fat
pad (MFP) model, the harvested MDA-MB-435-MLE cells were
suspended in PBS buffer (pH 7.4) andmixedwith BDMatrigel™ (BD
Bioscience, USA) at 1:1 ratio. Cell suspension was subcutaneously
injected into the mammary fat pad of the female NSG mice aged
4e6 weeks (Charles River, UK) at a concentration of 5.0  105 cells
in 20 mL. For SPECT/CT imaging studies, both models were
Fig. 1. Amino acid sequence of the wild type (WT) and recombinant HBc particles
used in this study. Wild-type HBc (WT-HBc) protein consists of an assembly domain
(grey colour) and an arginine-rich domain (white colour). In the truncated HBc (DHBc)
particles, the arginine-rich domain (150e183 aa) was deleted. In the HER2-targeting
HBc (ZHER2-DHBc) particles, a ZHER2 affibody (blue colour) was inserted between 78
and 81 aa. For all constructs, His-tag (red colour) was fused to the C-termini to aid
protein purification. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
Table 1
Yield and size characterisation of WT-HBc, DHBc and ZHER2-DHBc particles.
HBc particles Protein yield (mg)a,c OD260:OD280a,c Size ± SD (nm)b,d
WT-HBc 3.21 ± 0.21 0.58 ± 0.01 33.77 ± 4.58
DHBc 3.73 ± 0.58 0.62 ± 0.06 30.24 ± 2.87
ZHER2- DHBc 3.13 ± 0.23 0.56 ± 0.05 32.41 ± 2.33
a Values were obtained with Nanodrop from 1 L bacteria containing media.
b Values were obtained with Atomic Force Microscopy (AFM).
c Results are expressed as an average ± SD (n ¼ 3).
d Results are expressed as an average ± SD (n ¼ 50).
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River, UK).
After inoculation, the tumour growth was analysed by biolu-
minescent imaging of mice every 7 days, from day 7 post-
inoculation, using IVIS Lumina series III In Vivo Imaging Device
(IVIS) (Perkin Elmer, the Netherlands). Mice were subcutaneously
injected D-luciferin (150 mg of luciferin/kg) (Perkin Elmer, the
Netherlands). Animals were imaged at 12 min post-injection and
analysed using Living Image software (Perkin Elmer, the
Netherlands). Photon flux from the tumour is proportional to the
number of live cells expressing luciferase.
2.2.11. Live small animal SPECT/CT imaging studies
DHBc and ZHER2-DHBc particles were radiolabelled with 99mTc as
described in previous sections. Whole body imaging of mice
injected with 99mTc-DHBc or 99mTc-ZHER2-DHBc particles was car-
ried out using SPECT/CT imaging. For the intraperitoneal model,
MDA-MB-435-MLE tumour-bearing SCID/Beige mice were injected
intraperitoneally in the right lower quadrant of the abdomen with
150 ml PBS solution containing 6e14 MBq 99mTc-DHBc or 99mTc-
ZHER2-DHBc particles (corresponding to 200 mg protein/mouse). For
the mammary fat pad model, MDA-MB-435-MLE tumour-bearing
SCID/Beige mice were injected intratumourally with 10 ml PBS so-
lution containing 4e9 MBq 99mTc-DHBc or 99mTc-ZHER2-DHBc par-
ticles (corresponding to 200 mg protein/mouse). SPECT/CT imaging
was carried out at 0e30 min, 4 h and 24 h post-injection under
anaesthesia with 1.5% isoflurane/98.5% oxygen using Nano-SPECT/
CT Scanner (Bioscan, Washington DC, USA). SPECT acquisitions
were obtained using 24 projections over 30 min using a four-head
scanner with 1.4 mm pinhole collimators. CT scans were carried out
after the SPECT acquisition. SPECT and CT images were analysed
using InVivoScope™ software (Bioscan, Washington DC, USA).
2.2.12. Quantitative biodistribution studies by gamma scintigraphy
Quantitative biodistribution studies of radiolabelled 99mTc-HBc
particles including organ biodistribution, blood circulation and
excretion profile were performed in intraperitoneal or mammary
fat pad models of MDA-MB-435-MLE tumour-bearing NSG mice
using gamma. Mice were randomly divided into three groups of
three mice each; [99mTc(CO)3]þ, 99mTc-DHBc or 99mTc-ZHER2-DHBc
group. For the intraperitoneal model, mice were injected intra-
peritoneally via the right lower quadrant of the abdomen with
150 mL PBS solution containing 4e6 MBq 99mTc-DHBc or 99mTc-
ZHER2-DHBc particles (corresponding to 50 mg protein/mouse). For
the MFP model, mice were injected intratumourally with 150 mL or
10 mL PBS solution containing 4e6MBq 99mTc-DHBc or 99mTc-ZHER2-
DHBc (corresponding to 50 mg protein/mouse), respectively.
Equivalent volumes and radioactivity of [99mTc(CO)3]þ alone was
used as a negative control. Tumours and other organs and tissues,
i.e. skin, liver, spleen, heart, lung, muscle, bone (femur), brain,
stomach, intestine, tail and carcass were removed, weighed and the
radioactivity was measured by a gamma counter (1280 Compu-
Gamma Universal Gamma Counter, LKB Wallac, Finland), using the
appropriate windows for 99mTc. Results were expressed as a per-
centage of injected dose per gram tissue (%ID/g of tissues) as
means ± SD (n ¼ 3).
3. Results
3.1. Plasmids construction
All plasmids depicted in Fig. 1 were constructed and prepared as
described by Y. Nishimura et al. [22]. Plasmid expressing WT-HBc
[22] with His6-tag-fused at the C-terminal was constructed. A
full-length monomer consists of 183 aa residues (Fig. 1). A plasmidexpressing truncated HBc (DHBc [22]) was constructed to reduce
the non-specific binding capacity of WT-HBc particles, by deletion
of the sequence encoding arginine-rich domains. Finally, a plasmid
expressing ZHER2-DHBc [22] was constructed, by inserting a HER2
target-cell-specific affibody, ZHER2 between 78 and 81 aa sequences
of the DHBc monomer to express the targeting moiety within HBc
particles. All HBc plasmids were used to transform E. coli, and HBc
proteins were expressed, purified and re-assembled as described in
the ‘Methods’ section.3.2. Protein yield and purity
The yield and characteristics of the various particles are shown
in Table 1. A OD260/OD280 ratio greater than 0.6 indicates nucleic
acid contamination in the protein samples [23].3.3. Size and morphological examination of assembled HBc
particles
The diameter of WT-HBc particles was in the range of
33.77 ± 4.58 nm obtained by atomic force microscopy (AFM)
(Table 1). The removal of the arginine-rich domain sequence or the
introduction of ZHER2 affibody did not lead to statistically significant
differences in HBc particles' diameters (Table 1).
The morphology of assembled HBc particles was examined
initially by AFM. As shown in Fig. 2A, HBc particles are spherical in
shape and showed a homogenous size distribution. Expectedly,
when HBc particles were dissociated by dilution in distilled water,
the “dis-assembled” particles resulted in irregular and ‘broken’
structures, confirming that the addition of distilled water was an
Fig. 2. Morphological analysis of purified HBc core particles with Atomic Force Microscopy (AFM) and Cryo-Transmission Electron Microscopy (Cryo-TEM). (A) AFM images
using tapping mode AFM (TM-AFM) and (B) cryo-EM images of HBc particles. Dis-assembled HBc were achieved by dilution in distilled water at 40 C for 10 min. In A, HBc particles
were deposited on the mica substrates and measurements were carried out in air at 25 C using a Bruker Dimension ICON with Scan Assist. In B, 3 mL of 10 mg/mL assembled HBc
particles solution was applied on hydrophilic TEM Quantifoil grids and plunged into the liquid ethane pool to produce a thin vitreous ice layer. Cryo-TEM images were acquired
using a FEI Tecnai Spirit operated at 120 kV using a Gatan 626 cryo-transfer tomography holder. Dis-assembled HBc appeared as irregular structures while assembled HBc (WT-HBc,
DHBc, and ZHER2-DHBc) particles appeared spherical in shape.
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particle shape occurred with the deletion of arginine-rich domain
(DHBc) or insertion of ZHER2 affibody (ZHER2-DHBc) Fig. 2A. The 2D
bright-field projections from cryo-TEM suggested that all HBc
particles, shown as electron-dense nanoparticles, are spherical in
shape confirming the success of the self-assembly process (Fig. 2B).3.4. Western blotting of HBc particles
Western blotting analysis was performed by immune-blotting
using anti-6-His and anti-HBc antibodies to confirm the expres-
sion and purification of all HBc particle types. Results showed the
presence of specific protein bands at the expected molecular
weight bands using both antibodies at 21 kDa, 17 kDa and 24 kDa
for HBc, DHBc and ZHER2-DHBc, respectively (Fig. 3). This confirms
the successful expression and purification of HBc particles.3.5. Intracellular uptake of HBc particles in cancer cells in vitro
HER2 expression levels in a range of cancer cell lines were
examined using flow cytometry. Based on the “mean fluorescence
intensity” (MFI) values, HER2 expression levels on cells were
ranked in the following order: MDA-MB-468 < MDA-MB-
231 < SKBR-3 < BT-474. Cells were classified as negative () (MDA-
MB-468), low expressing (þ) (MDA-MB-231) or over expressing
(þþþ) (SKBR-3, BT-474) for HER2 receptors (See Supplementary
Information, Fig. S1).
The intracellular uptake of fluorescently labelled Alexa Fluor™
488 WT-HBc, DHBc and ZHER2-DHBc in breast cancer cells; MDA-
MB-468, MDA-MB-231, SKBR-3 and BT-474 was evaluated with
flow cytometry using the FL-1 detector. Degree of uptake was
expressed as a fold increase in MFI compared to naïve cells. All cells
were treated for 1, 4 or 24 h with HBc particles at increasing con-
centrations of 10, 20 or 40 mg/mL. The fold increase in MFI of cells
Fig. 3. Immuno-specificity of HBc particles by Western blotting. Denatured HBc samples were subjected to SDS-PAGE followed by immune-blotting using anti-6-His and anti-
HBc antibodies. Results confirmed the presence of specific protein bands at the expected molecular weight band; 21 kDa, 17 kDa and 24 kDa for WT-HBc, DHBc and ZHER2-DHBc,
respectively.
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by cancer cells in a time- and dose-dependent manner (Fig. S2,
Fig. 4). All cancer cells treated with DHBc particles showed very
little increase in the fold increase in MFI, indicating a significant
reduction in intracellular uptake of the truncated particles, sup-
porting the hypothesis that the deletion of the arginine-rich
domain can reduce the non-specific binding ability of WT-HBc
particles. In contrast, treatments with ZHER2-DHBc particles in the
HER2-positive cell lines, SKBR-3 (green bars) and BT-474 (purple
bars) cells, promoted an apparent fold increase in a time- and dose-
dependent manner. In contrast, MDA-MB-231 (orange bars) cells
treated with ZHER2-DHBc particles observed a lower value in fold
increase whereas MDA-MB-468 (blue bars) cells exhibited the least
(Fig. 4). These results indicate that specific uptake of ZHER2-DHBc
particles in HER2 (þ) and (þþþ) cells occurs in a time- and dose-
dependent manner in accordance with HER2 expression levels in
cells.3.6. 99mTc radiolabelling of HBc particles and stability studies
99mTc radiolabelling of assembled HBc particles was performed
as described by Badar et al. [17] with modifications. [99mTcO4]- was
activated to [99mTc(CO)3]þ by adding the IsoLink kit followed by
heating and adjusting the pH to 7.0e7.5,. NaCl was added upon the
mixing of [99mTc(CO)3]þ with DHBc or ZHER2-DHBc particles to
achieve the final [Naþ] concentration of 0.63 M, to achieve high
radiochemical yield (95%) [17]. Radiolabelling efficiency was
determined using iTLC. At 60 min post-incubation, both DHBc and
ZHER2-DHBc showed radiolabelling efficiency of 89.9% and 90.5%,
respectively. The radiolabelling efficiency increased to 97.2%
(**p < 0.01) and 98.0% (**p < 0.01) for DHBc and ZHER2-DHBc,
respectively, after 120 min post-incubation (Fig. 5A). Radiolabelled
99mTc-DHBc and 99mTc-ZHER2-DHBc were then purified with 10 kDa
MWCO Vivaspin to remove any unbound [99mTc(CO)3]þ, and ex-
change the buffer with PBS to achieve isotonic condition. As shown
in Fig. 5B, no unbound [99mTc(CO)3]þ was observed in both 99mTc-
DHBc and 99mTc-ZHER2-DHBc dispersions. A good radiolabelling
stability of 99mTc-DHBc and 99mTc-ZHER2-DHBc in PBS and 50%serum incubated at 37 C for 24 h was also obtained (Fig. 5C).3.7. Whole body SPECT/CT imaging and organ biodistribution of IP-
administered HBc particles in the IP tumour model
Two different tumour-bearing mice models, through intraperi-
toneal (IP) and mammary fat pad (MFP) inoculation were used for
in vivo studies (See Supplement Information Fig. S3). Solutions
containing only [99mTc(CO)3]þwas used as control (See Supplement
Information, Figs. S4-S6). Short blood circulation times, and hence
poor tumour accumulation, were observed in mice given radio-
labelled 99mTc-DHBc or 99mTc-ZHER2-DHBc via intravenous injection
in both tumourmodels (Figs. S7eS8). Local administration intoMFP
tumours and IP injection for the IP tumour model were therefore
attempted. SPECT/CT imaging was performed followed by ex vivo
gamma counting of major organs. Three-dimensional reconstruc-
tion of the whole animal by SPECT/CT imaging was conducted
immediately after injection (<30 min), 4 h and 24 h post-injection.
Quantitative studies by gamma counting were performed at 24 h
post-injection.
Following IP injection, both types of HBc particles exhibited a
wide-spread pattern in the abdominal cavity at 0e30 min, with
signals started to appear in bladder at 4 h post-injection. Interest-
ingly, stronger signals were associated with the tumour masses in
the case of 99mTc-ZHER2-DHBc compared to 99mTc-DHBc¼ especially
at 24 h post-injection (Fig. 6A and Fig. S9A far-right panel, white
arrow). Excretion profiles can be seen in Supplementary Informa-
tion, Fig. S10A. Major organ biodistribution profiles of 99mTc-DHBc
showed the uptake in kidneys > liver > spleen with 10.27 ± 1.59,
4.54 ± 1.06 and 2.84 ± 0.24%ID/g of tissue at 24 h post-injection,
respectively (Fig. 6B, black bars). 99mTc-ZHER2-DHBc exhibited
comparable profile except for the kidney (6.69 ± 0.87%ID/g,
*p < 0.05) (Fig. 6B, grey bars). Matching the SPECT/CT results, a
significantly higher accumulation in tumour uptake of 99mTc-ZHER2-
DHBc (9.12 ± 0.11%ID/g, *p<0.05) (grey bars) was observed
compared to 99mTc-DHBc (5.00 ± 0.89%ID/g) (black bars) at 24 h
post-injection (Fig. 6B).
Fig. 4. In vitro targeting studies using HBc particles. (A) Fluorescence intensity histogram of cells treated with WT-HBc particles. (B) Fold increase in median fluorescence in-
tensity, relative to naïve cells, of cells treated with fluorescently labelled Alexa Fluor™ 488WT-HBc, DHBc or ZHER2-DHBc particles at increasing concentrations of 10, 20 or 40 mg/mL.
Flow cytometry confirmed the non-specific uptake of WT-HBc particles by cancer cell lines in a time- and dose-dependent manner. DHBc particles showed a significant reduction in
uptake, supporting the hypothesis that the deletion of the arginine-rich domain can reduce the non-specific binding ability of wild type HBc particles. Specific uptake of ZHER2-DHBc
particles in HER2 (þ) and (þþþ) cells is occurred in a time-, dose- and HER2-dependent manner. Values are expressed as fold increase ±SD. *P < 0.05, **P < 0.01, ***P < 0.001,
relative to MDA-MB-468 cell line (one-way ANOVA test).
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studies of locally (IT)-administered HBc particles in the MFP tumour
model
SPECT/CT imaging exhibited similar biodistribution profiles for99mTc-DHBc (Fig. S9B) and 99mTc-ZHER2-DHBc (Fig. 7A), where most
of the signals appeared in the MFP tumours and some radioactivity
was seen in the bladder. Excretion profiles can be seen in Supple-
mentary Information (Fig. S10B). Gamma counting showed accu-
mulation of 99mTc-DHBc in the kidneys > liver > spleen with
Fig. 5. Radiolabelling efficiency, purification and in vitro serum stability of recombinant HBc particles by phosphor imaging. (A) The radiolabelling reaction was carried out at
37 C and monitored for 2 h with labelling efficiency determined at 60 and 120 min. 97.2% and 98.0% radiolabelling efficiency was achieved for DHBc and ZHER2-DHBc, respectively.
(B) 99mTc-DHBc and 99mTc-ZHER2-DHBc was purified from free [99mTc(CO)3]þ and buffer exchanged with PBS buffer using 10 kDa MWCO Vivaspin. Both types of HBc particles
exhibited 100% radiolabelling efficiency. (C) Serum stability was tested by incubation of 99mTc-DHBc and 99mTc-ZHER2-DHBc in 50% serum or PBS buffer at 37 C up to 24 h. Both types
of HBc particles exhibited 100% stability in serum and PBS indicated by no [99mTc(CO)3]þ at the solvent front.
I.F.B. Mohamed Suffian et al. / Biomaterials 120 (2017) 126e138 13318.32± 3.58, 6.03 ± 1.95 and 3.40± 1.28%ID/g of tissue, at 24 h post-
injection, respectively (Fig. 7B, black bars). A matching profile was
observed for 99mTc-ZHER2-DHBc (Fig. 7B, grey bars). There was
slightly higher but not significant tumour uptake for 99mTc-ZHER2-
DHBc (31.06 ± 6.05%ID/g of tumour) compared to 99mTc-DHBc
(21.09 ± 3.12%ID/g of tumour) (Fig. 7B, inset).
The overall conclusion from these biodistribution studies is that
the IP tumour model seems to be a more suitable model for future
in vivo cancer therapy studies using HBc particles. Most impor-
tantly, the results provided solid evidence on the substantial
tumour accumulation and targeted uptake of ZHER2-DHBc particles
in HER2 (þþþ) tumours in vivo over the 24 h period studied.4. Discussion
Virus-like particles (VLPs) have been used as nano-carriers to
display foreign epitopes and also deliver small molecules to cells,
tissues or organs [24]. The strategy of using these VLPs as drug
delivery systems has attracted many researchers' attention to
combat many diseases, including cancer [24]. Among the VLPs, HBc
particles were one of the first models of ‘displaying nano-carriers’,
carrying different desired foreign epitopes on their surface
including for vaccination [24,25]. Much attention has been given to
HBc particles due to their high-level production in well-known
homologous and heterologous expressions systems, such as
Escherichia coli, and their correct self-assembly ability into core
Fig. 6. In vivo SPECT/CT imaging and organ biodistribution studies of IP-administered 99mTc-HBc particles in MDA-MB-435-MLE IP tumour-bearing NSG mice. Mice were
intraperitoneally injected with 99mTc-DHBc (black bars) or 99mTc-ZHER2-DHBc (grey bars) at a dose of 50 mg protein/mouse (4e6 MBq per mouse). Organs were excised at 24 h post-
injection for gamma counting. (A) Whole body SPECT/CT imaging at 0e30 min, 4 and 24 h post-injection of 99mTc-ZHER2-DHBc. Green arrow indicates the location of the
administration. White arrow indicates accumulation in the tumour at 24 h post-injection. (B) Organ biodistribution profile with values expressed as %ID/g of tissue. Inset shows the
%ID/g tumour uptake. A significant increase in tumour uptake was shown in the IP model treated with 99mTc-ZHER2-DHBc compared with mice treated with 99mTc-DHBc (*p < 0.05).
Results are expressed as mean ± SD (n ¼ 3). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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as mentioned earlier, the native or wild type HBc particles are
known for their non-specific binding properties, due to the
positively-charged arginine-rich domain located at 150e183 aa
[7,10]. To address this issue, Nishimura et al. has developed re-
combinant HBc particles, where the non-specific binding of wild
type HBc particles was reduced by genetically deleting the
arginine-rich domain of 150e183 aa region [22,30]. It has been
reported that the arginine-rich domain is not required for correctassembly of HBc particles. Therefore, deletion of this poly-arginine
region does not affect their structure and particle assembly [30,31].
A HER2 targeting system was developed by expressing ZHER2
affibodies on the spike of the truncated HBc particles (DHBc). The
ZHER2 affibody was introduced into the major immunodominant
region (MIR) of 78e81 amino acids (aa) position of the HBc core
protein. This 78-81 aa of MIR region forms the tips on the particles'
spikes thus are exposed and accessible on the surface of the HBc
particles, making it available for cell-receptor-ligand interaction
Fig. 7. In vivo SPECT/CT imaging and organ biodistribution studies of locally-administered 99mTc-HBc particles in MDA-MB-435-MLE MFP tumour-bearing NSG mice. Mice
were intratumourally injected with 99mTc-DHBc (black bars) or 99mTc-ZHER2-DHBc (grey bars) at a dose of 50 mg protein/mouse (4e6 MBq per mouse). Organs were excised at 24 h
post-injection for gamma counting. Green arrows indicate the location of the administration. (A) Whole body SPECT/CT imaging at 0e30 min, 4 and 24 h post-injection of 99mTc-
ZHER2-DHBc. (B) Organ biodistribution profile with values expressed as %ID/g of tissue. Inset shows the %ID/g tumour uptake. No significant increase in tumour uptake was shown in
MFP model treated with 99mTc-ZHER2-DHBc compared with mice treated with 99mTc-DHBc (p > 0.05). Results are expressed as mean ± SD (n ¼ 3). (For interpretation of the ref-
erences to colour in this figure legend, the reader is referred to the web version of this article.)
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employed to express HER2 targeting moiety since they lack the
arginine rich-domain, which is responsible for the non-specific
binding of HBc to a variety of cells. Results in this study showed
that non-specific uptake was observed when all four different
breast cancer cell lines, MDA-MB-468, MDA-MB-231, SKBR-3 and
BT-474 were treated with WT-HBc particles. The arginine-rich
domain of HBc particles has been well studied, specifically on its
function and effects on the particles' assembly and nucleic acidbinding [7,33,34]. It has been demonstrated that the arginine-rich
domain binds the cell surface heparan sulphate proteoglycan via
electrostatic interactions. Studies have shown that any proteinwith
either an arginine-rich domain or a protein transduction domain
(PTD) will bind the heparan sulphate proteoglycan on a cell surface,
resulting in a non-specific binding of native or wild type HBc par-
ticles to any cells including cancer cells [35e37]. It has also been
reported that the engineered DHBc particles lacking the arginine-
rich domain, specifically arginine residues in aa 150e159, could
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would reduce its function of cell binding and uptake [22,38]. This
agrees with results obtained in this study where the removal of the
entire arginine-rich domain from the HBc particles structure
managed to significantly reduce the cell uptake of HBc particles
when the cancer cells were treated with DHBc particles.
The main concern of using HBc particles or any virus-like par-
ticles is the immunogenicity. The MIR region is known for its
function to elicit a strong antibody response including a strong B
cell, T helper cell and cytotoxic T cell response. An introduction of
targeting moieties at theMIR regionwill not only optimally remove
a strong antibody response against the native MIR; but it also al-
lows the inserted sequences to be available at the surface of the
particle to bind specifically its target receptor [39,40].
Our work is different from previously reported study [22], in
that, an optimised expression protocol was used for the expression,
purification and assembly of HBc particles. The results showed that
treating MDA-MB-468, MDA-MB-231, SKBR-3 and BT-474 cells at
increasing concentrations of HBc particles at 10, 20 or 40 mg/mL
resulted in specific uptake in a time- and dose-dependent manner.
This is an extension of Nishimura et al.’s work in which HBc par-
ticles at concentrations up to 10 mg/mL were tested [22].
A variety of nanoparticles including VLPs are being developed
for biomedical applications [41e46]. However, information
regarding their biological behaviours in vivo is still limited. In-
terventions, such as routes of administration, biodistribution pat-
terns and pharmacological profiles, are important for the design
and development of successful bio-nanoparticles for future clinical
and cancer therapeutic studies [47,48]. In the current study, we
analysed the behaviour of recombinant HBc particles, specifically
truncated recombinant HBc particles (DHBc) and HER2-targeting
ZHER2 affibodies-expressing recombinant HBc particles (ZHER2-
DHBc), in two HER2 (þþþ) MDA-MB-435-MLE tumour bearing
NSG mice models, namely, IP and MFP tumour models. While
orthotopic or ectotopic implantation of cancer cells in the MFP
provides a well-defined model to mimic early stages of breast
cancer growth [49,50], IP tumour mouse model offers close rep-
resentation of clinical disease progression of tumour, including
metastatic dissemination [51,52]. HBc particles were administered
in these two models via the systemic (intravenous or intraperito-
neal injection) or local (intratumoural) routes.
In order to investigate the biodistribution qualitatively and
quantitatively, HBc particles were radiolabelled with the radionu-
clide technetium-99 m (99mTc). 99mTc is used to trace small protein
(<55 kDa) with a half-life sufficiently long 6 h) to allow for radio-
labelling and biodistribution studies to be carried out. It also has
favourable photon energy for imaging while minimising patient
radiation-absorbed dose. Radiolabelling can be achieved using site-
specific labelling methods that exert maximum control over the
number and site modification(s) to the molecule, without altering
the protein function [53]. In this study, the His-tag located at the C
terminal of the recombinant HBc particles was used to site-
specifically radiolabel the protein with 99mTc-tricarbonyl
([99mTc(CO)3]þ). This method was firstly developed by Waibel et al.
[54] then further modified by Badar et al. [53]. The His-tag was
originally used to facilitate purification of the HBc particles using
metal chelate-based affinity chromatography [55]. Histidine has
been a favourable binding ligand to [99mTc(CO)3]þ compared to
other amino acids as the labelling efficiency and stability increase
with the increased number of histidines present [56]. Using the
technique reported by Badar et al., radiolabeling efficiency of >95%
was achieved for both particles. High radiolabelling efficiency is
ideal (~95%), as low labelling efficiency can hamper quantitative
measurements and imaging sensitivity. Furthermore, an additional
purification step prior to imaging will be required which may causeexcessive dilution and losses of the protein due to its irreversible
binding to columns and filters [53].
The clearance kinetics of proteins and VLPs have been reported
in several studies [3,57e59]. In general, particulate materials
including viral proteins are removed from the blood circulation
relatively quickly by the reticulo-endothelial system (RES) (e.g. liver
and spleen) [60,61]. For example, Singh et al. reported that the
retention time of lanthanide-Cowpie mosaic virus (CPMV) particles
in bloodstreamwas about 15e30 min [3]. Adenovirus (Ad) particles,
reported by Green et al. also appear to be sequestered from circu-
lation in part by RES in mice, presumably by interaction with the
scavenger receptors or platelets [62]. Here, we also observed the
relatively rapid clearance from blood stream of intravenously-
administered HBc particles in both intraperitoneal and mammary
fat pad tumour models, similar to CPMV and Ad particles. The lack
of significant differences in tumours uptakes observed between the
two types of HBc particles in both tumour models might be due to
their short blood circulation times. This rapid clearance of HBc
particles suggests that modification with polyethylene glycol (PEG)
or other masking agents might be required to prolong the blood
circulation times of the particles [63,64]. Raja et al. reported that
CPMV particles coated with PEG managed to reduce the particle's
uptake in liver and spleen, causing a prolonged blood circulation
time in mice [65].
Quantitative studies by gamma counting exhibited significant
tumour accumulation by IP or IT injection of HBc particles. A sig-
nificant tumour targeting effect was observed in the case of IP in-
jection of 99mTc-ZHER2-DHBc particles in the IP tumour model. The
peritoneal cavity is the site of disease in several cancers, including
ovarian, gastrointestinal and peritoneal mesothelioma. After in-
jection into the peritoneal cavity, a drug or a nanocarrier, is taken
up by the surrounding peritoneal tissues, and from there spread
into other body compartments via the circulation [66]. Using the IP
route not only avoids systemic distribution of the drug, but also
provides high concentrations, locally, which are then able to act on
the peritoneal tissues directly [67]. Many studies have shown the
use of the IP route for cancer therapy including chemotherapy.
Dedrick et al. demonstrated the pharmacokinetic rationale for
peritoneal drug administration in the treatment of ovarian cancer,
as the tumour can be exposed to higher concentrations of chemo-
therapeutics for prolonged periods of time if given intraperitone-
ally, rather than intravenously [68]. In addition to administering
drugs, the interest of using the peritoneal cavity to deliver gene
therapy agents has been increasing. Conclusive results have been
achieved in ovarian and pancreatic tumour bearing mice models
with adenoviral and retroviral particles, respectively [69,70].
Another study using a mice model of ovarian cancer looked at the
effects of small interfering RNA (siRNA), incorporated into lipo-
somal carriers. The results showed a combination of IP adminis-
tration with paclitaxel drugs was able to reduced tumour growth
compared to paclitaxel/control siRNA by 48e81%, which was
comparable to mice treated with paclitaxel and siRNA through IV
administration route [71]. These findings suggest the therapeutic
potential of IP route for drug delivery, which may have an impor-
tant role in the treatment of intra-abdominal malignancies in the
future.
However, we also observed a good retention of the non-targeted
HBc particles in the IP tumour mice model even at 24 h post
treatment. The chosen in vivo tumour line, MDA-MB-435-MLE,
exhibited a vascularised tumour property. This might be one of the
factors that contributed to the retention of the DHBc particles.
However, the HER2-targeted HBc particles (ZHER2-DHBc) exhibited
a significantly higher retention in the tumour (*p < 0.05) compared
to the DHBc particles, so that we could conclude that our ZHER2-
DHBc particles exhibited a significant enhancement in uptake in
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In IT-administered HBc particles in mammary fat pad tumour
model, we observed good retention of both HBc particles but also
[99mTc(CO)3]þ in the tumours. It has been discussed about the
challenges encountered in intratumoural administration of drug
delivery agents [72,73]. Despite the good retention in the tumour,
this may not necessarily translate to good uptake into cancer cells.
Barriers to homogenous distribution of nanoparticle in the tumour
tissues include the extracellular matrix [74,75], relatively high
interstitial fluid pressure [76] and affinity of the particles for the
tumour cells in the peripheral region of a solid tumour [77]. Our
study suggests that IP administration of the engineered HBc par-
ticles results in high accumulation of intraperitoneal tumour
models.
On the other hand, many articles have referred to and used
MDA-MB-435 (parental cell line of MDA-MB-435-MLE) as a breast
cancer tumour model. However, recent studies by Prasad et al.
showed that the MDA-MB-435 cell line was not a breast cancer cell
but instead a type of melanoma cell line [78]. Therefore, this cell
line will not be affected by the difference level of hormones.5. Conclusions
In summary, we developed genetically modified HBc particles
that specifically recognise and target human epidermal growth
factor receptor-related (HER2)-expressing cancer cells. In vitro
studies showed specific uptake of ZHER2-DHBc particles in HER2
expressing cancer cells. It is envisaged that this HER2-targeting HBc
can be loaded with drugs or any small molecules such as siRNA via
the dis-assembly/re-assembly processes. In vivo studies showed
that the combination of IP administration and the use of targeted
HBc particles (99mTc-ZHER2-DHBc) resulted in significantly
enhanced tumour accumulation in the intraperitoneal tumour
model, suggesting selective uptake of ZHER2-DHBc particles in HER2
(þþþ) tumours in vivo. Findings from this work offer fundamental
knowledge on the biodistribution of newly reported recombinant
HBc particles designed for local delivery of nucleic acids to intra-
peritoneal cancer.Acknowledgements
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